Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $26.1 million.

  • Prime Medicine's Share-based Compensation rose 86.71% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year increase of 25.00%. This contributed to the annual value of $26.1 million for FY2024, which is 87.40% up from last year.
  • Prime Medicine's Share-based Compensation amounted to $26.1 million in FY2024, which was up 87.40% from $13.9 million recorded in FY2023.
  • In the past 5 years, Prime Medicine's Share-based Compensation ranged from a high of $26.1 million in FY2024 and a low of $391,000 during FY2020.
  • In the last 3 years, Prime Medicine's Share-based Compensation had a median value of $13.9 million in 2023 and averaged $15.5 million.
  • Data for Prime Medicine's Share-based Compensation shows a peak YoY spiked of 346.55% (in 2021) over the last 5 years.
  • Prime Medicine's Share-based Compensation (Yearly) stood at $391,000 in 2020, then surged by 346.55% to $1.7 million in 2021, then skyrocketed by 269.93% to $6.5 million in 2022, then soared by 115.36% to $13.9 million in 2023, then spiked by 87.40% to $26.1 million in 2024.